scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Current status of COVID-19 vaccination: safety and liability concern for children, pregnant and lactating women

TL;DR: The current development of various CO VID-19 vaccine platforms for different groups of people at higher risk of COVID-19, with a special focus on children, pregnant and lactating women, as well as structural and pathogenicity elements of SARS CoV-2 are highlighted.
Journal ArticleDOI

Recent advances in respiratory immunization: A focus on COVID-19 vaccines

TL;DR: In this paper , the structure of the respiratory tract and the mechanisms of mucosal immunity, as well as the obstacles to respiratory vaccination are discussed, and the considerations necessary in constructing a COVID-19 respiratory vaccine, including the dosage form of the vaccines, potential excipients and mucosal adjuvants, and delivery systems and devices for respiratory vaccines.
Journal ArticleDOI

Uptake of COVID-19 booster shot among healthcare workers: A mediation analysis approach

TL;DR: It is demonstrated that unfavorable vaccination responses in healthcare workers significantly affect their likelihood of receiving booster shots, and awareness of these post-vaccination adverse events should be extensively integrated into immunization awareness programs and policy measures supporting booster doses.
Journal ArticleDOI

Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective

TL;DR: In this article , the authors formulated a generalized optimization problem with a total of uT=∑i=1nui vaccine doses, that have to be optimally distributed between n different sub-populations, where sub-population ui represents people receiving the ith dose of the vaccine with efficacy αi .
Journal ArticleDOI

COVID-19 vaccine-induced thrombotic thrombocytopenia

TL;DR: In response to the COVID-19 pandemic, scientists developed 69 vaccines in just 1 year, including the AstraZeneca and Johnson & Johnson adenovirus vector-based vaccines as discussed by the authors .
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -